Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas

Epidermal growth factor receptor (EGFR) mutation is prevalently expressed in lung adenocarcinoma cases and acts as one of the major driving oncogenes. EGFR tyrosine kinase inhibitors (TKIs) have been used in patients with EGFR-mutant as an effective targeted therapy in lung adenocarcinoma, but drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ting-Fang, Tseng, Yu-Chi, Nguyen, Phung Anh, Li, Yu-Chuan, Ho, Chao-Chi, Wu, Cheng-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762715/
https://www.ncbi.nlm.nih.gov/pubmed/29321482
http://dx.doi.org/10.1038/s41598-017-18527-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762715/
https://www.ncbi.nlm.nih.gov/pubmed/29321482
http://dx.doi.org/10.1038/s41598-017-18527-z

Ejemplares similares